This is a single-center, randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of a white ginseng extract (KoreaGinseng F Max) for improving blood circulation in adults with poor peripheral blood flow.
A total of 100 adults aged 20 to under 65 years with platelet aggregation above 55% will be enrolled and randomly assigned in a 1:1 ratio to receive either the white ginseng extract or a matching placebo for 8 weeks. Each participant takes 3 tablets after breakfast and 3 tablets after dinner (6 tablets per day).
The main goal is to measure the change in ADP-induced platelet aggregation from baseline (Visit 2) to the end of treatment (Visit 4, Week 8). The study also assesses effects on coagulation measures, blood lipids, serotonin, blood pressure, white blood cell count, and overall safety.
Men or women aged 20 to under 65 years
Platelet aggregation response above 55% (satisfied for both collagen and ADP)
Provides voluntary written informed consent to participate
History of hypersensitivity or allergy to ginseng-containing products that may affect the results
Surgery under general anesthesia within 12 weeks before participation
Use of contraindicated products such as red ginseng or omega-3 fatty acids within 2 weeks before screening
Use of antiplatelet drugs such as aspirin within 2 weeks before screening (subjects on prophylactic aspirin <100 mg with unchanged dose/method may participate)
Parallel
KoreaGinseng F Max
Dietary supplementWhite ginseng extract; 3 tablets after breakfast and 3 tablets after dinner (6 tablets/day), oral, for 8 weeks.
Placebo
Dietary supplementMatching placebo control product; same dosing schedule and duration as the test product.
Change in ADP-induced platelet aggregation
Change in adenosine diphosphate (ADP)-induced platelet aggregation from baseline to end of treatment.
Percent change in ADP-induced platelet aggregation
from baseline to end of treatment
Change and percent change in prothrombin time (PT)
from baseline to end of treatment
Change and percent change in activated partial thromboplastin time (aPTT)
from baseline to end of treatment
Change and percent change in serum lipids (total cholesterol, HDL-C, LDL-C, triglycerides)
from baseline to end of treatment
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
